Very interesting!
If it was negative you would think the announcement would state the discontinuing of the trial or safety issues.
As Dalts says hopefully the higher dose 440x10(6) with intratumoral and intraventricular modalities are kicking the efficacy along. Or could it be a partial or complete response from any of the previous cohorts? Cohort 3 completed in January so hopefully that dose has seen eradication of tumours and those patients are on the road to recovery. It does say data from the phase 1 trial not specifically the phase 1 Cohort 4. We will know on Tuesday.
Here is more info on the Cohort 4 trial which initiated on 2nd March.
Good luck all especially those long term, it's been a bumpy road.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $28.14K | 7.037M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 243067 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 14771167 | 22 |
View Market Depth
| Last trade - 15.39pm 20/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |